NumerixS Investment Technologies Inc purchased a new position in GlaxoSmithKline plc (NYSE:GSK) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 6,700 shares of the pharmaceutical company’s stock, valued at approximately $268,000.
Several other institutional investors have also recently added to or reduced their stakes in GSK. Berman Capital Advisors LLC boosted its position in GlaxoSmithKline by 58.1% during the second quarter. Berman Capital Advisors LLC now owns 656 shares of the pharmaceutical company’s stock valued at $26,000 after buying an additional 241 shares during the period. Sigma Planning Corp boosted its holdings in shares of GlaxoSmithKline by 0.8% during the second quarter. Sigma Planning Corp now owns 32,090 shares of the pharmaceutical company’s stock worth $1,284,000 after purchasing an additional 250 shares during the period. Trillium Asset Management LLC lifted its holdings in GlaxoSmithKline by 2.2% in the second quarter. Trillium Asset Management LLC now owns 11,519 shares of the pharmaceutical company’s stock worth $461,000 after buying an additional 252 shares during the period. CIBC Private Wealth Group LLC lifted its holdings in GlaxoSmithKline by 1.8% in the second quarter. CIBC Private Wealth Group LLC now owns 14,824 shares of the pharmaceutical company’s stock worth $593,000 after buying an additional 261 shares during the period. Finally, Essex Financial Services Inc. lifted its holdings in GlaxoSmithKline by 4.0% in the second quarter. Essex Financial Services Inc. now owns 6,990 shares of the pharmaceutical company’s stock worth $280,000 after buying an additional 269 shares during the period. 11.12% of the stock is currently owned by hedge funds and other institutional investors.
GSK has been the subject of several research analyst reports. Societe Generale upgraded shares of GlaxoSmithKline from a “sell” rating to a “buy” rating in a report on Tuesday, September 3rd. Morgan Stanley restated an “underweight” rating on shares of GlaxoSmithKline in a report on Monday, June 17th. JPMorgan Chase & Co. restated a “neutral” rating on shares of GlaxoSmithKline in a report on Tuesday, August 13th. Jefferies Financial Group restated a “buy” rating on shares of GlaxoSmithKline in a report on Thursday, August 29th. Finally, ValuEngine lowered shares of GlaxoSmithKline from a “hold” rating to a “sell” rating in a report on Tuesday, September 10th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and three have given a buy rating to the company. GlaxoSmithKline has a consensus rating of “Hold” and an average target price of $41.79.
GlaxoSmithKline (NYSE:GSK) last announced its earnings results on Wednesday, July 24th. The pharmaceutical company reported $0.78 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.64 by $0.14. The business had revenue of $10.04 billion during the quarter, compared to the consensus estimate of $9.55 billion. GlaxoSmithKline had a net margin of 13.84% and a return on equity of 175.45%. Analysts forecast that GlaxoSmithKline plc will post 2.98 earnings per share for the current fiscal year.
In other news, Director Plc Glaxosmithkline purchased 177,777 shares of GlaxoSmithKline stock in a transaction that occurred on Tuesday, September 10th. The stock was bought at an average price of $45.00 per share, with a total value of $7,999,965.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 10.00% of the stock is owned by company insiders.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Featured Story: Cost of Equity For A Business, Investors
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.